The field of immuno-oncology (IO) focuses on using novel immunotherapies to enhance the body’s ability to fight cancer. Advances in IO are changing the standards of cancer care at an unprecedented pace, creating a challenge for oncologists and nurses to stay on top of the latest treatment developments.
The European Immuno-Oncology Clinic Companion (EIOCC) is a needs-based, multicomponent educational initiative designed to support and facilitate increased knowledge, competence, and performance among oncology professionals involved in the use of IO agents.
Giuseppe Curigliano, MD, PhD
Professor and Head of the Division of Early Drug Development European Institute of Oncology
Peter Schmid, MD, PhD, FRCP
Professor of Cancer Medicine
Lead, Centre for Experimental Cancer
Medicine Lead, Cancer Immune Therapy Group Barts Cancer Institute
Who is EIOCC for?
EIOCC activities are designed for all members of the cancer care team, from those who are seeking a refresher course on the immune system to more experienced professionals who wish to challenge themselves with complex patient cases in immuno-oncology. The EIOCC audience includes, but is not limited to:
- Clinical oncologists
- Nurses, including oncology nurses
- Oncology residents and specialists in training
- Radiation oncologists
- Surgical oncologists
What topics are covered?
We invite learners to start with a Self-Assessment Activity to gauge their current levels of knowledge, competence, and confidence in the field of immuno-oncology. Additional EIOCC eLearning activities and webinars will focus on:
- Immune system and anticancer therapy
- Mechanisms of action of IO agents
- Response patterns and immune-related response criteria
- Pathophysiology of immune-related adverse events (irAEs)
- Challenging patient cases in IO
- Guidance on irAE management: ASCO/NCCN, ESMO, and SITC
- Setting up a multidisciplinary IO clinic
To support the evidence-based management of irAEs, the EIOCC programme includes a mobile and web-based point-of-care tool integrating the ASCO/NCCN, ESMO, and SITC guidelines. The EIOCC IO Toxicity Tool is offered as a new component of ONCOassist—the only oncology app classified as a medical device and CE-approved in European Economic Area (EU/EEA) countries to aid in clinical decisions.
Continuing medical education
All educational content is developed under the guidance of the EIOCC faculty with the support of Siyemi Learning, an independent CME provider accredited by ACCME. Additional details on CME credit designations are listed before each activity.
EIOCC is a multi-supported initiative supported by independent medical educational grants from Pfizer, Merck KGaA, and Bristol-Myers Squibb.